In einer Studie zu unerwnschten gastrointestinalen Wirkungen bei adipsen Nichtdiabetikern, die GLP-1-Agonisten (Semaglutid oder Liraglutid) zur Gewichtsabnahme einsetzten, wurde ein signifikant erhhtes Risiko fr Pankreatitis (Entzndung der Bauchspeicheldrse) und Ileus (Dnndarmverschluss) und festgestellt
Semaglutide may be inappropriate for people with label-listed contraindications, certain pregnancy or breastfeeding situations, or medical histories that raise concern for serious gastrointestinal, gallbladder, pancreatic, kidney, or mental health complications
It found that semaglutide: Was not associated with an increased risk of neurological and psychiatric conditions, such as dementia, depression, or anxiety, compared to other common anti-diabetic medications
Many patients find value in connecting with others who are on similar protocols, sharing before and after experiences , discussing strategies for managing side effects, and troubleshooting common challenges
Nearly a decade later, the Food and Drug Administration (FDA) issued the first approval for a GLP-1 analog to treat obesity
